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Microfibrillar-associated protein 4 
variation in symptomatic peripheral artery 
disease
Line Ea Hemstra1, Anders Schlosser1, Jes Sanddal Lindholt2,3 and Grith L. Sorensen1* 
Abstract 
Background: Symptomatic peripheral artery disease (PAD) is an atherosclerotic occlusive disease affecting the lower 
extremities. The cause of symptomatic PAD is atherosclerosis, vascular dysfunctions, impaired angiogenesis and neoin-
tima formation. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein, which is highly expressed 
in the heart and arteries and recently introduced as a potential mediator of pathological vascular remodeling and 
neointima formation. We aimed to investigate the relationship between serum MFAP4 (sMFAP4) and symptomatic 
PAD outcomes.
Methods: A total of 286 PAD patients were analyzed if they had either intermittent claudication or critical lower-
extremity ischemia (CLI) and followed for 7 years. The level of serum MFAP4 (sMFAP4) was measured by alphaLISA. 
Kaplan–Meier, Cox proportional hazard and logistic regression analysis were used to analyze the associations between 
upper tertile sMFAP4 and symptomatic PAD outcomes.
Results: Patients with upper tertile sMFAP4 had an odds ratio (OR) of 2.65 (p < 0.001) for having CLI diagnosis. Further 
analysis indicated that patients with upper tertile sMFAP4 had a hazard ratio (HR) of 1.97 (p = 0.04) for cardiovascular 
death during the 7-years follow-up. However, analysis of 2-year primary patency showed that patients with upper 
tertile sMFAP4 had decreased risk of vascular occlusion after reconstructive surgery with HR of 0.15 (p = 0.02).
Conclusions: sMFAP4 has potential as a prognostic marker for cardiovascular death, primary patency of recon-
structed vessels and CLI diagnosis in symptomatic PAD patients. Confirmation of observations in larger cohorts is 
warranted.
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Background
Peripheral artery disease (PAD) is an atherosclerotic vas-
cular disease that affects the blood vessels other than 
those in the coronary circulation. The cause of symp-
tomatic PAD is atherosclerosis, vascular dysfunctions, 
impaired angiogenesis and neointima formation and 
the prevalence is increased with age and is a growing 
health problem worldwide. It has been estimated that 
approximately 10% of men between 65 and 74 years have 
PAD [1], which is associated with an increased mortal-
ity rate of 25–30% [2–5]. Studies of the future need for 
vascular surgery in PAD patients predicts that vascular 
procedures will increase from 1.39 million in 2015 to 1.6 
million in the adult population by 2020 in US [6].
Symptomatic PAD can present as intermittent clau-
dication (IC) or as critical lower-extremity ischemia 
(CLI). CLI is a life-treating syndrome and associated 
with high risk of amputation [7–10]. The proportion of 
diagnosed CLI patients is approximately 40% of hospi-
talized PAD patients [11]. The clinical manifestations 
of the disease are seen after the establishment of the 
flow-limiting atherosclerotic plaque and symptoms 
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include intermittent claudication leg pain, rest pain, 
and ischemic ulcers. PAD patients further present with 
increased cardiovascular mortality [12] and increased 
functional decline compared to non-PAD [13]. The 
current treatment includes lifestyle changes, surgical 
revascularization [14] and medical therapy targeted 
at lowering atherosclerotic vascular diseases, which 
results in significant lowering of morbidity and mor-
tality associated with PAD [15]. Consequently, tar-
geted screening of at-risk patients using measurements 
of ankle–brachial index (ABI) is recommended [16]. 
Moreover, serum biomarkers have been used experi-
mentally for the prediction and detection of PAD [17, 
18], but although clear associations have been demon-
strated, the overall clinical value related to patient out-
comes remains unclear.
As such, identification of new biomarkers of symp-
tomatic PAD is vital for early discovery and treatment 
of patients. Indication of biological processes, for 
instance, resulting in increased risk of needing vascu-
lar reconstruction or developing CLI has the potential 
to reduce the worsening of symptoms and thus the 
morbidity and mortality of symptomatic PAD patients. 
In the present study, we envisioned that microfibrillar-
associated protein 4 (MFAP4) could serve as such a 
marker.
MFAP4 is an oligomeric extracellular matrix (ECM) 
protein belonging to the fibrinogen-related domain 
(FReD) super family, which also includes members 
such as angiopoietin and tenascin [19]. Besides the 
C-terminal FReD, the MFAP4 sequence harbors a 
N-terminal RGD sequence with integrin binding and 
activating capacity [20–22]. MFAP4 directly binds to 
collagen, elastin and fibrillin [23] and it is localized to 
ECM fibers in the heart and arteries throughout the 
body [24]. Mfap4-deficient mice have been generated 
but did not reveal any distinct role of MFAP4 in nor-
mal physiology, although the adult mice developed a 
mild airspace enlargement compatible with subtle elas-
tic defects [25]. In contrast, in vivo studies have dem-
onstrated direct roles for MFAP4 in vascular occlusive 
remodeling with delayed neointimal formation and 
blunted outward remodeling after carotid ligation in 
Mfap4-deficient mice [22]. MFAP4 is further found 
in a soluble form and serum MFAP4 (sMFAP4) levels 
are recognized to vary with cardiovascular disease [24] 
and pulmonary disease [26] although the strongest 
association is found with high sMFAP4 and liver cir-
rhosis [27–29]. In the present study, we hypothesized 
that sMFAP4 is positively associated with the symp-
tomatic PAD outcomes cardiovascular disease (CVD) 
death, 2-year primary patency after reconstructive sur-
gery, and CLI.
Methods
PAD patients
Five hundred and seven patients were consecutively 
included during November 1999 to December 2008. The 
patients had either intermittent claudication (IC) or criti-
cal lower-extremity ischemia (CLI) and were enrolled in 
the study at Vascular Surgery Department, Viborg Hospi-
tal, Denmark [30]. The PAD diagnosis was assessed dur-
ing the clinical examination. Cases with acute lower limb 
ischemia were excluded. Serum samples (centrifuged at 
2000×g for 10  min) were available for sMFAP4 meas-
urements from 373 patients and we included data from 
all patients who were followed for 7 years. Patients with 
incomplete medical records of date of death or sMFAP4 
measurements were thus excluded and a total of 286 (165 
men and 121 women) patients with complete medical 
records were included in the final analyses.
A thorough medical history was recorded for all 
patients. Clinical information came from medical records 
or directly from patients. Patients were characterized 
as current smokers or as nonsmokers if they had previ-
ously been smoking or never had been smoking. Diabe-
tes was defined by history of diabetes mellitus or the use 
of oral anti-diabetic drugs and/or insulin. Hypertension 
was diagnosed upon interview. Hypertension was defined 
by any history of hypertension with use of anti-hyper-
tensive drugs for that purpose. Deaths from all causes 
were identified in the Danish National CPR-registry (the 
centralized civil register in Denmark). In addition, the 
patients were followed in the nationwide Danish registry 
of Vascular Surgery (Karbasen) for need for later surgery 
during the 7  years follow-up period and moreover for 
primary patency the first 2  years. Primary CVD causes 
of death were identified by International Classification of 
Disease-10 codes in the I01.0 through I99.9, and sudden 
death [31].
AlphaLISA measurements of serum samples
The AlphaLISA immunoassay technique was used for 
detection of sMFAP4 in patient samples as previously 
described by Wulf-Johansson et al., detection is based on 
simultaneous target recognition by two different mono-
clonal anti-MFAP4 antibodies [24].
Statistical methods
Continuous variables are presented as median with 95% 
confidence intervals. Continuous data are compared 
using Kruskal–Wallis test. Categorical variables are pre-
sented as n (proportion) and compared with the Chi 
square test. Kaplan–Meier and Cox proportional hazard 
analysis were used to analyze the risk of CVD death and 
all-cause mortality during the 7-year follow-up period 
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and the risk of vascular occlusion after reconstructive 
surgery for patients divided into upper sMFAP4 tertile 
and lower/middle sMFAP4 tertiles. A log rank test was 
performed for each survival analysis, to test the differ-
ences between the groups. Logistic regression was used 
to analyze the risk of a CLI diagnosis and hazard ratios 
(HRs) with 95% confidence intervals were calculated for 
upper tertile sMFAP4 with age, sex, body mass index 
(BMI) and smoking as covariates. A p value < 0.05 was 
considered statistical significant. StataIC 14 (http://www.
stata .com) was used to perform the analyses.
Results
Baseline observations
Baseline characteristics divided into lower/middle tertile 
sMFAP4 and upper tertile sMFAP4 are shown in Table 1. 
The lower/middle tertile sMFAP4 included 190 patients 
and the upper tertile sMFAP4 included 96 patients. 
Analysis of clinical variables between these two groups 
showed, that there was a significant difference when 
considering age (p = 0.01), male sex (p = 0.02), smoking 
(p = 0.03), CLI/IC diagnosis (p < 0.001), whereas there 
was a tendency for BMI-association to MFAP4 tertiles. 
The unadjusted baseline characteristics did not reveal 
increased proportions of patients with upper tertile 
sMFAP4 amongst those who died from cardiovascular 
causes during follow-up.
Baseline characteristics divided into patients with and 
without vascular surgery are shown in Additional file 1: 
Table S1. Analysis of clinical variables between these two 
groups showed, that there was a significant difference 
when considering critical limb ischemia (CLI)/intermit-
tent claudiacation (IC) diagnosis (p < 0.001).
Endpoint distribution
Figure 1 shows the distribution and a limited overlap of 
patients with the clinical endpoints CVD death, vascu-
lar occlusion and the CLI diagnosis. The additional 115 
patients who had IC diagnosis with no vascular occlusion 
or CVD death are not included in the figure.
Table 1 Baseline characteristics divided into sMFAP4 lower/middle tertiles and upper tertile
Continuous variables are presented as median (95% confidence interval) and compared using Kruskal–Wallis test. Categorical variables are presented as n (proportion) 
and compared with the Chi square test
Lower tertile/middle tertile
(n = 190)
Upper tertile
(n = 96)
p-value
Age (years) 65.1 [63.2; 66] 69 [65.8; 69.6] 0.01
Male sex 119 (66%) 46 (48%) 0.02
Body mass index (kg/m2) 24.6 [24.8; 25.9] 24.2 [23.8; 25.5] 0.05
Smoking 119 (66%) 49 (51%) 0.03
Hypertension 96 (51%) 46 (48%) 0.68
Previous stroke 3 (2%) 2 (2%) 0.76
Diabetes mellitus 29 (15%) 17 (18%) 0.59
Statin 37 (19.5%) 17 (18%) 0.55
ACE inhibitors 34 (18%) 21 (22%) 0.60
Critical limb ischemia 76 (40%) 61 (64%) < 0.001
Intermittent claudication 114 (60%) 35 (36%) < 0.001
Reconstructive surgery at baseline and during follow up 61 (32%) 28 (29%) 0.61
Cardiovascular death during follow up 24 (13%) 19 (20%) 0.11
CVD death CLI
Occlusion
3
27 107
6
18
10
0
Fig. 1 Distribution of patients, who were diagnosed with critical 
limb ischemia (CLI) at baseline, died of cardiovascular diseases (CVD 
death) or had a vascular occlusion after reconstructive surgery. Those 
patients who were diagnosed with intermittent claudication at 
baseline and did not suffer from CVD death or vascular occlusion are 
not included
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Symptomatic PAD patients with upper tertile sMFAP4 have 
significantly increased risk of CLI in adjusted analysis
Adjusted logistic regression analysis of patients with a 
CLI diagnosis (Table 2) showed that patients with upper 
tertile sMFAP4 have a significant OR of 2.65 (p < 0.001; 
95% CI [1.56; 4.50]) for CLI diagnosis at baseline.
Symptomatic PAD patients with upper tertile sMFAP4 
have significantly increased risk of cardiovascular death 
during follow-up in adjusted analysis
Kaplan–Meier analysis (Fig. 2) and Cox regression (Addi-
tional file  1: Table  S2) showed that patients with upper 
tertile sMFAP4 had a significant HR of 1.97 (p = 0.04; 
95% CI [1.05; 3.70]) for cardiovascular death during 
the 7-year follow-up period. Log rank test of equality 
between the two groups showed a significant difference 
(p = 0.02) between patients with upper tertile sMFAP4 
and lower/middle tertile sMFAP4 and the risk of cardio-
vascular death.
Kaplan–Meier analysis and Cox regression further 
showed that patients with upper tertile sMFAP4 had 
insignificantly (p = 0.07) increased all-cause mortality, 
with a borderline difference (p = 0.05) when comparing 
the two groups with a log rank test for equality (Fig. 3 and 
Additional file 1: Table S3).
Symptomatic PAD patients with upper tertile sMFAP4 
have significantly decreased risk of vascular occlusion 
in the 2-year period after reconstructive surgery
Kaplan–Meier survival analysis (Fig.  4) was performed 
for occlusion of reconstructed vessels within an obser-
vation period of 2  years following reconstructive sur-
gery. Log rank test for equality supported a significant 
(p = 0.02) difference between patients with upper tertile 
sMFAP4 and lower/middle tertile sMFAP4 when ana-
lyzing the risk of vascular occlusion. The data further 
showed that patients with upper tertile sMFAP4 had a 
decreased risk of occlusion of the reconstructed vessel 
with a HR of 0.15 (p = 0.02) (Additional file 1: Table S4).
Discussion
The purpose of this study was to investigate whether 
sMFAP4 was positively associated with the follow-
ing symptomatic PAD outcomes; CLI diagnosis, CVD 
death, and 2-year primary patency after vascular recon-
struction. We observed a significant direct correlation 
between the upper sMFAP4 tertile and CLI. In addition, 
we observed that upper tertile sMFAP4 was significantly 
associated with CVD death in analyses adjusting for 
age, sex, smoking and BMI. Surprisingly, patients with 
upper tertile sMFAP4 had a significantly decreased risk 
of occlusion of their reconstructed vessel. The latter rela-
tionship may be explained by that there is a rather limited 
overlap between those patients with vascular occlusion 
after surgery, and CVD death and/or CLI in the present 
cohort (Fig. 1). Thus, a large proportion of patients with 
vascular occlusion after reconstructive surgery had IC 
(18/27) and no CVD death or CLI and sMFAP4 may be 
regulated differently in IC versus CLI or processes lead-
ing to CVD death.
This is to our knowledge the first observation that 
associates sMFAP4 to CLI, CVD death, and vascular 
occlusion after reconstructive surgery and the observa-
tion supports the hypothesis that sMFAP4 may serve 
Table 2 Adjusted logistic regression analysis of risk of CLI 
diagnosis at baseline in symptomatic PAD patients
Odds ratio Std. err. p-value 95% conf. interval
Upper tertile 
sMFAP4
2.65 0.71 < 0.001 1.56; 4.50
Age 1.02 0.01 0.201 0.99; 1.04
Male sex 1.53 0.40 0.103 0.92; 2.56
Body mass index 
(kg/m2)
1.02 0.04 0.588 0.95; 1.09
Smoking 0.72 0.19 0.204 0.43; 1.20
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Fig. 2 sMFAP4 upper tertile association with cardiovascular disease 
(CVD) death in symptomatic PAD patients during 7 years follow-up. 
A log rank test shows a significant difference (p = 0.02) between the 
two groups
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Fig. 3 Kaplain-Meier survival estimate of all-cause mortality divided 
by sMFAP4 upper tertile. A log rank test for equality shows a p-value 
of 0.05 between the two groups
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as a prognostic marker in symptomatic PAD. As such, 
sMFAP4 has the potential to identify patients that are 
in risk of developing CLI or CVD death. However, it is 
currently unknown if high sMFAP4 develops as a con-
sequence of disease and if a series of consecutive meas-
urements therefore might be more informative than the 
present baseline measurement. Moreover, the study was 
not originally designed to test if inclusion of sMFAP4 
into risk assessment based on ABI and Framingham risk 
scores would add value to a screening program.
Previous studies of clinical sMFAP4 variation showed 
that the level of sMFAP4 can be correlated to the other 
cardiovascular risk markers; fibulin-1, osteoprotegerin 
and ostepontin [24]. Basic studies performed by our 
group have shown that MFAP4 is involved in vascular 
smooth muscle hyperplasia, neointima formation and 
vascular remodeling in  vivo [22]. The former studies in 
Mfap4-deficient mice have thus identified a mechanistic 
role of MFAP4 in vascular biology involved in vascular 
complications of PAD. Other observations have shown 
that both local MFAP4 expression and serum levels of 
MFAP4 are increased in liver fibrosis/cirrhosis [28, 29, 
32] and moreover are moderately regulated in COPD 
[26]. On this basis, we do not suggest that MFAP4 is a 
disease-specific marker for symptomatic PAD.
A possible explanation of our present observations 
of the increased level of sMFAP4 in symptomatic PAD 
patients with the most severe outcomes may be that 
vascular bed remodeling and/or ischemia causes tis-
sue disruption and release of ECM molecules, including 
MFAP4, into the circulation as seen previously [33]. The 
surprising association between the lowest sMFAP4 and 
increased risk of vascular occlusion after reconstructive 
surgery could indicate that certain events occurring in 
the vessels may contribute to destruction of MFAP4 as it 
is seen for matricellular proteins such as osteopontin [34, 
35]. However, it was not examined if or to what degree 
sMFAP4 was degraded in the present study.
Limitation of the present study is furthermore that we 
do not have matched controls, that uncontrolled con-
founding and information bias might be present and that 
there was limited follow-up on CVD death in this study. 
Thus larger cohorts are warranted to confirm our obser-
vations. The strength of this study is that the prospective 
design has been used previously in several studies [30, 
36–38]. Moreover, a relatively long duration of follow-up 
is present in this study.
Conclusion
The present analysis shows that patients with upper ter-
tile sMFAP4 have a significantly increased risk of CLI 
diagnosis and CVD death in adjusted analysis. Further 
analysis of risk of vascular occlusion within the first 
2 years after reconstructive surgery shows a significantly 
decreased risk in patients with upper tertile sMFAP4. 
Validating analyses of these associations in larger cohorts 
are required to confirm that sMFAP4 may serve as a 
prognostic marker of CLI development and CVD death 
in symptomatic PAD.
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